Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7334449 | 0.98 | ESRRG (0.52) | ESRRGCA2CA1ALDH1A1POLB | |
| SCHEMBL6433557 | 0.84 | KDM4E (0.61) | ESRRGCA2CA1ALDH1A1POLB | |
| SCHEMBL4179064 | 0.84 | HPGD (0.57) | CA2CA1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4702861 | 0.83 | ALDH1A1 (0.47) | CA2CA1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5553483 | 0.83 | PLAAT3 (0.58) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6275214 | 0.83 | SMN1; SMN2 (0.47) | CA2CA1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1094537 | 0.83 | CNR1 (0.57) | SMN1; SMN2GFER | |
| SCHEMBL419646 | 0.83 | CNR1 (0.50) | CA2CA1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL14141265 | 0.83 | NPC1 (0.59) | CA2CA1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL27353884 | 0.83 | ESRRG (0.54) | ESRRGCA2CA1SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335902-B1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1345892-B1 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA GMBH (DE) | 2005-03-09 | — | — | EP | disclosed |
| EP-1183236-B1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA GMBH (DE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1345892-A2 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| EP-1335902-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-6511989-B2 | For therapy of vagal dysfunction in the heart, improving cardiac function, therapy of person susceptible to cardiac death | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-28 | — | — | US | disclosed |
| EP-0713483-B1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-6472413-B2 | FOR THERAPY OF VAGAL DYSFUNCTION IN THE HEART, IMPROVING CARDIAC FUNCTION, THERAPY OF PERSON SUSCEPTIBLE TO CARDIAC DEATH | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-20020123494-A1 | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2000071513-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-30 | — | — | WO | disclosed |
| US-6132957-A | CONTACTING A 9-SUBSTITUTED ADENINE WITH A CELL EXTRACT CONTAINING ADENYLATE CYCLASE ACTIVITY, DETECTING THE AMOUNT OF INHIBITION, AND CORRELATING WITH TEST STANDARD OR CONTROL; NOVEL THERAPIES FOR CARDIOVASCULAR DISORDERS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2000-10-17 | — | — | US | disclosed |
| US-6030985-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 2000-02-29 | — | — | US | disclosed |
| US-5807885-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 1998-09-15 | — | — | US | disclosed |
| US-5795756-A | Method and compounds for the inhibition of adenylyl cyclase | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 1998-08-18 | — | — | US | disclosed |
| US-5773469-A | Diaryl antimicrobial agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997048674-A1 | DIARYL ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
| CN-1132505-A | Amidine derivatives with nitric oxide synthetase activities | ASTERA CO (SE) | 1996-10-02 | — | — | CN | disclosed |
| EP-0713483-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | Astra Aktiebolag (SE) | 1996-05-29 | — | — | EP | disclosed |
| WO-1995005363-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRA AKTIEBOLAG (SE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | ESRRG 717/4885CA2 650/4885CA1 990/4885 |
| US-20020123494-A1 | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | KCNJ11, KCNJ1, KCNA1 | ESRRG 4702/4885CA2 438/4885CA1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.